Register Now for an NPC Webinar:

Let’s Get Real: How Will the FDA Framework for Real-world Evidence Impact You?

Join the Conversation on Wednesday, Jan. 30, from 1 p.m.-2 p.m. ET
 

Last month, the U.S. Food and Drug Administration (FDA) released its framework for evaluating the potential use of real-world evidence (RWE) to help support the approval of a new indication for a pre-approved medicine and satisfy post-approval study requirements. Development of the framework was required under the 21st Century Cures Act and is a first step toward meeting those requirements. But how is RWE really being used and how will the FDA framework affect decision-makers beyond the FDA?

Please join the National Pharmaceutical Council and experts for a webinar on Jan. 30 from 1 p.m. to 2 p.m. ET that will showcase the potential implications of the FDA framework for patients, payers, manufacturers and other health care stakeholders.

Speakers include:
Jennifer Graff, PharmD
Vice President of Comparative Effectiveness Research, National Pharmaceutical Council
Eleanor Perfetto, PhD, MS
Senior Vice President of Strategic Initiatives,
National Health Council
Tricia Lee Wilkins, PharmD, MS, PhD
Director of Pharmacy Affairs, Academy of Managed Care Pharmacy
Brande Yaist, MHS
Senior Director of the Center of Expertise in Global Patient Outcomes and Real-World Evidence, Eli Lilly and Company

This webinar will provide:

  • An overview of how the FDA currently uses RWE, and what a future in which RWE is commonly used might look like;
  • A deeper dive into new research describing the current use and contribution of RWE, the implications for and needs of the patient and patient advocacy community, and how the patient community is preparing for broader use of RWE;
  • A payer’s perspective on the current use of RWE, how the payer community is preparing to use RWE more consistently, and whether the standards for RWE for payment and coverage will be similar or different from the standards for regulatory decisions; and
  • An industry perspective describing how industry is using RWE today, how this may or may not change due to the FDA framework, and how the framework will affect evidence development intended for other health care decision-makers.

>> Register now to join the webinar on Wednesday, Jan. 30, at 1 p.m. ET.

For more information on using RWE and other evidence-related related topics, visit NPC's website.

 
Tweet
Share
Share
 
About the National Pharmaceutical Council
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information visit www.npcnow.org and follow NPC on Twitter @npcnow.
 
This Industry Leaders Update was sent on behalf of NPC by HealthEconomics.Com, 449 S. Mill View Way, Ponte Vedra Beach, FL 32082.
If you don't wish to receive further Industry Leaders News Updates from us, you may immediately unsubscribe from this list here , or send your request in writing to the address above. Read more about our privacy policy here. You may also request a copy in writing using the address above.